In the April–June 2015 edition of Corporate Disputes, Dr. Gregory Bell and Professor Iain Cockburn discuss damages in the pharmaceutical and biotech sector . To read more, click on the link below.
Keytruda LoE: Does it end or exacerbate the combination pricing problem?
Achieving price solutions for combination regimens that are mutually acceptable to both industry and payers in global healthcare systems, is a challenge that...